Epicore lands $26m to advance wearable sensors that provide real-time insights into hydration, stress, nutrition, and overall wellness.
Digital health company Epicore Biosystems has secured $26 million in Series B funding to accelerate the global adoption of its sweat-sensing wearables and analytics platform. The company said the funding will also support the expansion of its technology into new biomarkers, including kidney health, women’s health, malnutrition and exposure to environmental toxins.
A spinout from Northwestern University’s Querrey Simpson Institute for Bioelectronics and the John Rogers Laboratory, Epicore has developed a range of clinically validated biowearable products that provide wearers with real-time health insights. The company says its wearables, already deployed worldwide, have been licensed by major corporations, the Department of Defense and the National Institute of Health.
Epicore was initially focused on helping athletes maximize performance and recovery, and developed its Gx Sweat Patch in collaboration with PepsiCo and Gatorade. Since then the company has also launched products designed to help combat the risks associated with excessive heat exposure and environmental toxins, such as those faced by industrial workers, and its technology is now deployed in areas including energy, construction, manufacturing and aviation.
Epicore’s sweat-sensing wearables non-invasively measure sweat composition and fluid loss, offering immediate insights into hydration, stress, nutrition and overall wellness. By integrating biochemical and metabolic health data with conventional digital biomarkers, the technology alerts users to potential risks such as dehydration, heat injury, or malnutrition, enabling proactive intervention.
While Epicore is currently focused on specific demographics, the company’s co-founder and CEO Dr Roozbeh Ghaffari, CEO, said the new funding will facilitate broader distribution and accelerate the validation of additional biomarkers that can benefit wider populations.
“The Series B investment will help expand our global reach and accelerate the validation of new biomarkers needed to shape the future of personalized hydration and wellness strategies for all,” he said.
The funding round was led by the Steele Foundation for Hope, and its CEO Joe Exner, said: “Epicore’s commitment to improving personalized health for those in critical need aligned strongly with our mission to improve the quality of life for people in need worldwide.”
